AVNS · As filed with the SEC

Avanos Medical income statement, by quarter

The statement as Avanos Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

CONDENSED CONSOLIDATED INCOME STATEMENTS · USD, except per-share amounts

USD, except per-share amountsQ1 2026
3 months ended Mar 31, 2026
Q4 2025†
3 months ended Dec 31, 2025
Q3 2025
3 months ended Sep 30, 2025
Q2 2025
3 months ended Jun 30, 2025
Net Sales182,200,000180,900,000†177,800,000175,000,000
Cost of products sold88,000,00094,900,000†91,800,00082,900,000
Gross Profit94,200,00086,000,000†86,000,00092,100,000
Research and development5,200,0006,100,000†6,000,0005,800,000
Selling and general expenses77,700,00078,800,000†77,600,00083,500,000
Goodwill impairment——077,000,000
Other expense (income), net2,400,000(1,400,000)†2,300,000300,000
Operating Income8,900,0002,500,000†100,000(74,500,000)
Interest income200,000600,000†500,000600,000
Interest expense(1,500,000)(1,900,000)†(1,800,000)(2,000,000)
Income before income taxes7,600,0001,200,000†(1,200,000)(75,900,000)
Income tax provision(2,500,000)(2,500,000)†(200,000)(900,000)
Loss from Continuing Operations—(1,300,000)†(1,400,000)(76,800,000)
Loss from discontinued operations, net of tax—0†00
Net Income5,100,000(1,300,000)†(1,400,000)(76,800,000)
Earnings Per Share
Continuing operations (in dollars per share)——(0.03)(1.66)
Discontinued operations (in dollars per share)——0.000.00
Basic (in dollars per share)0.11—(0.03)(1.66)
Continuing operations (in dollars per share)——(0.03)(1.66)
Discontinued operations (in dollars per share)——0.000.00
Diluted (in dollars per share)0.11—(0.03)(1.66)

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.